Related references
Note: Only part of the references are listed.A Higher Antibody Response Is Generated With a 6-to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval
Brian Grunau et al.
CLINICAL INFECTIOUS DISEASES (2022)
Robust and durable serological response following pediatric SARS-CoV-2 infection
Hanna Renk et al.
NATURE COMMUNICATIONS (2022)
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Rebecca P. Payne et al.
CELL (2021)
SARS-CoV-2 Seroprevalence in Germany A Population-Based Sequential Study in Seven Regions
Daniela Gornyk et al.
DEUTSCHES ARZTEBLATT INTERNATIONAL (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Review Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis
P. Galanis et al.
JOURNAL OF HOSPITAL INFECTION (2021)
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
Matthias Becker et al.
NATURE COMMUNICATIONS (2021)
Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
Jacqui Wise
BMJ-BRITISH MEDICAL JOURNAL (2021)
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
Ariel Israel et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Antibody-mediated procoagulant platelets in thrombotic thrombocytopenia
Karina Althaus et al.
HAEMATOLOGICA (2021)
Trajectory of COVID-19 Vaccine Hesitancy Over Time and Association of Initial Vaccine Hesitancy With Subsequent Vaccination
Aaron J. Siegler et al.
JAMA NETWORK OPEN (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Andreas Greinacher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
Anton Pottegard et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination
Rishi R. Goel et al.
SCIENCE IMMUNOLOGY (2021)
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
David W. Eyre et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Deborah Steensels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu et al.
LANCET (2021)
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
Edward J. Carr et al.
LANCET (2021)
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Tina Schmidt et al.
NATURE MEDICINE (2021)
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros-Martins et al.
NATURE MEDICINE (2021)
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
Emma Pritchard et al.
NATURE MEDICINE (2021)
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
Talia Kustin et al.
NATURE MEDICINE (2021)
Covid-19 Vaccine Effectiveness and the Test-Negative Design
Natalie E. Dean et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
Dan H. Barouch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
M. G. Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
Minal K. Patel et al.
VACCINE (2021)
Evidence for antibody as a protective correlate for COVID-19 vaccines
Kristen A. Earle et al.
VACCINE (2021)
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Matthias Becker et al.
NATURE COMMUNICATIONS (2021)
Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021
Heather M. Scobie et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
Wesley H. Self et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
Monika Strengert et al.
EBIOMEDICINE (2021)
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Benjamin Israelow et al.
SCIENCE IMMUNOLOGY (2021)
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
Ester Lopez et al.
JCI INSIGHT (2021)
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
Paul Naaber et al.
LANCET REGIONAL HEALTH-EUROPE (2021)
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
John S. Tregoning et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
Site-specific glycan analysis of the SARS-CoV-2 spike
Yasunori Watanabe et al.
SCIENCE (2020)
Potently neutralizing and protective human antibodies against SARS-CoV-2
Seth J. Zost et al.
NATURE (2020)
Broad neutralization of SARS-related viruses by human monoclonal antibodies
Anna Z. Wec et al.
SCIENCE (2020)
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
Supriya Ravichandran et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
The complexities of SARS-CoV-2 serology Comment
Catherine F. Houlihan et al.
LANCET INFECTIOUS DISEASES (2020)
Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition
Oliver C. Grant et al.
SCIENTIFIC REPORTS (2020)
Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals
Georg M. N. Behrens et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Humoral Responses and Serological Assays in SARS-CoV-2 Infections
Yannick Galipeau et al.
FRONTIERS IN IMMUNOLOGY (2020)
Systematic reference sample generation for multiplexed serological assays
Hannes Planatscher et al.
SCIENTIFIC REPORTS (2013)